Cost-effectiveness analyses and utility weights
Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles.
2 cost-effectiveness analyses and 1 study reporting utility weights · 3 sources
Overview
| Item | Detail |
|---|---|
| Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. |
| Cost-effectiveness analyses | 2 |
| Studies reporting utility weights | 1 |
Cost-effectiveness analyses
Analyses of Atebrioz (zilurgisertib and INCB000928)
No evidence found.
Treatments for the same indication
No evidence found.
The same disease in other populations or settings
No evidence found.
Related diseases and analogous treatments
Deflazacort versus prednisone in Duchenne muscular dystrophy, United States: ICER (2019)
Relevance: Evaluates deflazacort against prednisone in Duchenne muscular dystrophy in the United States with lifetime health states defined by ambulatory status, a structure a model of fibrodysplasia ossificans progressiva could adapt for the progression to wheelchair use described in section 2.2.1.3.
Asfotase alfa versus best supportive care in pediatric-onset hypophosphatasia, Canada: CADTH (2017)
Relevance: Evaluates asfotase alfa against best supportive care in pediatric-onset hypophosphatasia from the Canadian health care payer perspective over a lifetime, a government review of a chronic therapy for an ultra-rare genetic bone disorder in the same jurisdiction as the Canadian palovarotene review in section 4.1.
Utility weights
Utility weights from analyses of Atebrioz (zilurgisertib and INCB000928)
No evidence found.
Utility weights for the same indication
No evidence found.
Utility weights for the same disease in other populations or settings
No evidence found.
Utility weights for related diseases and analogous treatments
Patient and caregiver utility weights by functional score, ambulatory status, and ventilation status, Duchenne muscular dystrophy: Landfeldt et al. (2017)
Relevance: Patient and caregiver utilities by ambulatory status in Duchenne muscular dystrophy, health states that correspond to the progression to wheelchair use and lifelong dependence on assistance described for fibrodysplasia ossificans progressiva in section 2.2.1.3.
“Patient utilities (ranging from 0 = dead to 1 = perfect health) were obtained from the Health Utilities Index Questionnaire and caregiver utilities from the EuroQol EQ-5D-3L” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Search strategy
| Dataset | Query | Results |
|---|---|---|
| Ratios | zilurgisertib OR Atebrioz OR "INCB000928" OR palovarotene OR Sohonos OR garetosmab | 0 |
| Ratios | "fibrodysplasia ossificans progressiva" OR "heterotopic ossification" | 0 |
| Weights | "fibrodysplasia" OR "heterotopic ossification" OR palovarotene OR "ossification" | 0 |
| Methods | fibrodysplasia OR palovarotene OR "heterotopic ossification" OR "ALK2" | 0 |
| Ratios | achondroplasia OR vosoritide OR "osteogenesis imperfecta" OR hypophosphatasia OR "asfotase" OR "X-linked hypophosphatemia" OR burosumab | 2 |
| Weights | achondroplasia OR "osteogenesis imperfecta" OR hypophosphatasia OR "hypophosphatemia" OR "skeletal dysplasia" | 8 |
| Weights | "Duchenne" AND (ambulatory OR wheelchair OR ambulation) | 24 |
| Methods | zilurgisertib OR Atebrioz OR garetosmab OR Sohonos | 0 |